RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virusConsequently ONCY will likely be acquired before it has to commence enrolling any patients in its planned Phase 2 180-200 patient HR+/HER2- metastatic breadt cancer study, or shortly after the enrollment process starts. So while Kirk Look has speculated that it would take 3-5 years to receive both PDAC and mBC FDA approval. That timeline is for 2 approvals in 2 different indications that ONCY is expecting to move into registrational studies. Big Pharma has the resources and capacity to achieve Accelerated Approval in both in a matter of months, just based on the effectiveness of ONCY's surrogate endpoints of PFS, ORR and mBC, and I think that we will know Big Pharma's move relatively soon.